PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da Universidade Federal do Ceará (UFC) |
Texto Completo: | http://www.repositorio.ufc.br/handle/riufc/26626 |
Resumo: | Background: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT. |
id |
UFC-7_f93df618973e8fdbccb602b73432e284 |
---|---|
oai_identifier_str |
oai:repositorio.ufc.br:riufc/26626 |
network_acronym_str |
UFC-7 |
network_name_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository_id_str |
|
spelling |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapyHipersensibilidadeHypersensitivityImunoterapiaImmunotherapyBackground: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT.Journal of Chemical and Pharmaceutical Research2017-10-13T14:48:29Z2017-10-13T14:48:29Z2017info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfTRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017.0975 - 7384http://www.repositorio.ufc.br/handle/riufc/26626Trindade, R eginaldo Almeida daSant’Anna, Osvaldo Augusto Brazil EstevesRescia, Vanessa CristinaBruni, Fernanda MirianiLopes-Ferreira, Mônica Valdyrce dos AnjosSantos, Daiane Fernanda dosNicolete, RobertoFaccioli, Lucia HelenaAraujo, Pedro Soares deCosta, Maria Helena Bueno daengreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2019-01-25T14:27:27Zoai:repositorio.ufc.br:riufc/26626Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:47:18.865380Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false |
dc.title.none.fl_str_mv |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
title |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
spellingShingle |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy Trindade, R eginaldo Almeida da Hipersensibilidade Hypersensitivity Imunoterapia Immunotherapy |
title_short |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
title_full |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
title_fullStr |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
title_full_unstemmed |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
title_sort |
PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy |
author |
Trindade, R eginaldo Almeida da |
author_facet |
Trindade, R eginaldo Almeida da Sant’Anna, Osvaldo Augusto Brazil Esteves Rescia, Vanessa Cristina Bruni, Fernanda Miriani Lopes-Ferreira, Mônica Valdyrce dos Anjos Santos, Daiane Fernanda dos Nicolete, Roberto Faccioli, Lucia Helena Araujo, Pedro Soares de Costa, Maria Helena Bueno da |
author_role |
author |
author2 |
Sant’Anna, Osvaldo Augusto Brazil Esteves Rescia, Vanessa Cristina Bruni, Fernanda Miriani Lopes-Ferreira, Mônica Valdyrce dos Anjos Santos, Daiane Fernanda dos Nicolete, Roberto Faccioli, Lucia Helena Araujo, Pedro Soares de Costa, Maria Helena Bueno da |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Trindade, R eginaldo Almeida da Sant’Anna, Osvaldo Augusto Brazil Esteves Rescia, Vanessa Cristina Bruni, Fernanda Miriani Lopes-Ferreira, Mônica Valdyrce dos Anjos Santos, Daiane Fernanda dos Nicolete, Roberto Faccioli, Lucia Helena Araujo, Pedro Soares de Costa, Maria Helena Bueno da |
dc.subject.por.fl_str_mv |
Hipersensibilidade Hypersensitivity Imunoterapia Immunotherapy |
topic |
Hipersensibilidade Hypersensitivity Imunoterapia Immunotherapy |
description |
Background: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10-13T14:48:29Z 2017-10-13T14:48:29Z 2017 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
TRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017. 0975 - 7384 http://www.repositorio.ufc.br/handle/riufc/26626 |
identifier_str_mv |
TRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017. 0975 - 7384 |
url |
http://www.repositorio.ufc.br/handle/riufc/26626 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Journal of Chemical and Pharmaceutical Research |
publisher.none.fl_str_mv |
Journal of Chemical and Pharmaceutical Research |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Ceará (UFC) instname:Universidade Federal do Ceará (UFC) instacron:UFC |
instname_str |
Universidade Federal do Ceará (UFC) |
instacron_str |
UFC |
institution |
UFC |
reponame_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
collection |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC) |
repository.mail.fl_str_mv |
bu@ufc.br || repositorio@ufc.br |
_version_ |
1813028946849038336 |